Omission of local therapies in women patients with HER2-positive or triple-negative breast cancer. A two arm, phase 2, non-inferiority trial for surveillance in maximum responders to neoadjuvant systemic therapy.
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Gennaro Massimiliano
Main Facility: Chirurgia Senologica
Drug: Not Applicable
Pathologies: Breast cancer (TNBC)
HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after VABB (vacuum assisted breast biopsy) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for higly selected patients, in whom systemic treatments have provided the maximum response.
Last update: 12/05/2026